Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Functional monocytic myeloid-derived suppressor cells increase in blood but not airways and predict COVID-19 severity
Sara Falck-Jones, … , Anna Färnert, Anna Smed-Sörensen
Sara Falck-Jones, … , Anna Färnert, Anna Smed-Sörensen
Published January 25, 2021
Citation Information: J Clin Invest. 2021;131(6):e144734. https://doi.org/10.1172/JCI144734.
View: Text | PDF
Research Article Immunology

Functional monocytic myeloid-derived suppressor cells increase in blood but not airways and predict COVID-19 severity

  • Text
  • PDF
Abstract

The immunopathology of coronavirus disease 2019 (COVID-19) remains enigmatic, causing immunodysregulation and T cell lymphopenia. Monocytic myeloid-derived suppressor cells (M-MDSCs) are T cell suppressors that expand in inflammatory conditions, but their role in acute respiratory infections remains unclear. We studied the blood and airways of patients with COVID-19 across disease severities at multiple time points. M-MDSC frequencies were elevated in blood but not in nasopharyngeal or endotracheal aspirates of patients with COVID-19 compared with healthy controls. M-MDSCs isolated from patients with COVID-19 suppressed T cell proliferation and IFN-γ production partly via an arginase 1–dependent (Arg-1–dependent) mechanism. Furthermore, patients showed increased Arg-1 and IL-6 plasma levels. Patients with COVID-19 had fewer T cells and downregulated expression of the CD3ζ chain. Ordinal regression showed that early M-MDSC frequency predicted subsequent disease severity. In conclusion, M-MDSCs expanded in the blood of patients with COVID-19, suppressed T cells, and were strongly associated with disease severity, indicating a role for M-MDSCs in the dysregulated COVID-19 immune response.

Authors

Sara Falck-Jones, Sindhu Vangeti, Meng Yu, Ryan Falck-Jones, Alberto Cagigi, Isabella Badolati, Björn Österberg, Maximilian Julius Lautenbach, Eric Åhlberg, Ang Lin, Rico Lepzien, Inga Szurgot, Klara Lenart, Fredrika Hellgren, Holden Maecker, Jörgen Sälde, Jan Albert, Niclas Johansson, Max Bell, Karin Loré, Anna Färnert, Anna Smed-Sörensen

×

Figure 3

M-MDSCs isolated from patients with COVID-19 suppress T cell proliferation partly through the release of Arg-1.

Options: View larger image (or click on image) Download as PowerPoint
M-MDSCs isolated from patients with COVID-19 suppress T cell proliferati...
(A) Blood M-MDSCs isolated from patients with COVID-19 were cocultured with CFSE-labeled allogenic PBMCs in the presence of SEB for 3 days at a ratio of 1:2 (M-MDSCs/PBMCs). Histograms show representative CD4+ and CD8+ T cell proliferation as assessed by CFSE dilution and flow cytometry. The numbers in the plots indicate the frequency of proliferating T cells. (B) Dot plots show the percentage of proliferating CD4+ and CD8+ T cells with the median (n = 3). *P ≤ 0.05 and **P < 0.01, by Wilcoxon signed-rank test. (C) Isolated M-MDSCs were cultured with CFSE-labeled allogenic PBMCs in the presence of SEB for 3 days. The M-MDSC/PBMC ratios were 1:5 and 1:2. Dot plots show the percentage of proliferating CD4+ T and CD8+ cells with the median (n = 2). (D) Dot plots show IFN-γ levels in supernatants from cell cultures with the median (n = 2). (E–G) Isolated M-MDSCs were cultured with CFSE-labeled allogenic PBMCs in the presence of SEB and l-arginine for 3 days. The M-MDSC/PBMC ratio was 1:2. (E) Dot plots show Arg-1 levels in supernatants from cell cultures with the median (n = 2). ND, not detectable. (F and G) Dot plots show the percentage of proliferating (F) CD4+ T cells (n = 2) and (G) CD8+ T cells (n = 2) with the median.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts